“PrEP and PEP both involve taking HIV medications to prevent transmission of HIV. PrEP is taken daily and was FDA approved just this past year, while PEP is taken within 72 hours of exposure to HIV. To learn more about PrEP and PEP ask your doctor or visit: www.thebody.com or www.cdc.gov”
via The Stigma Project

PrEP and PEP both involve taking HIV medications to prevent transmission of HIV. PrEP is taken daily and was FDA approved just this past year, while PEP is taken within 72 hours of exposure to HIV. To learn more about PrEP and PEP ask your doctor or visit: www.thebody.com or www.cdc.gov

via The Stigma Project

“Within the last year, the U.S. Food and Drug Administration approved the following game-changing products for HIV: Oraquick’s In-Home HIV Testing Kit ($40); A once-daily, 4-in-1 single pill treatment regimen known as Stribild; and allowed Truvada, an HIV regimen, to be prescribed as an effective once-daily prevention tool. KNOW HIV = NO HIV”
via The Stigma Project

Within the last year, the U.S. Food and Drug Administration approved the following game-changing products for HIV: Oraquick’s In-Home HIV Testing Kit ($40); A once-daily, 4-in-1 single pill treatment regimen known as Stribild; and allowed Truvada, an HIV regimen, to be prescribed as an effective once-daily prevention tool. KNOW HIV = NO HIV

via The Stigma Project

Top 12 HIV and Hepatitis Stories of 2012
“In our last issue for 2012, HIVandHepatitis.com reviews some the year’s major HIV and viral hepatitis news highlights. On the HIV front, U.S. treatment guidelines recommended antiretroviral therapy (ART) for all HIV positive people, Truvada was approved for pre-exposure prophylaxis (PrEP), and HIV criminalization and cure research were highlighted at the International AIDS Conference in July. Promising findings were reported for several interferon-free oral regimens for hepatitis C, experimental tuberculosis (TB) drugs showed good results, and the Affordable Care Act remained on track…”
read more at HivandHepatitis.com

Top 12 HIV and Hepatitis Stories of 2012

In our last issue for 2012, HIVandHepatitis.com reviews some the year’s major HIV and viral hepatitis news highlights. On the HIV front, U.S. treatment guidelines recommended antiretroviral therapy (ART) for all HIV positive people, Truvada was approved for pre-exposure prophylaxis (PrEP), and HIV criminalization and cure research were highlighted at the International AIDS Conference in July. Promising findings were reported for several interferon-free oral regimens for hepatitis C, experimental tuberculosis (TB) drugs showed good results, and the Affordable Care Act remained on track…

read more at HivandHepatitis.com

PrEP - Love May Have Another Protector
Check out this visually informative website on the benefits of PrEP (treatment as prevention) brought to you by the San Francisco AIDS Foundation

PrEP - Love May Have Another Protector

Check out this visually informative website on the benefits of PrEP (treatment as prevention) brought to you by the San Francisco AIDS Foundation

Anonymous asked: I just read something about Truvada (a new medication) that's supposed to prevent people from getting HIV when having sex with HIV positive partners.. I was wondering if you've heard of it and if there's any truth behind it?

Hi there,

Here’s a great post on POZ.com on everything you need to know about Truvada as PrEP (pre-exposure prophylaxis). I hope it helps!

Click here.